We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck's Zocor, Fosamax Take Hit From Generic Rivals
Merck's Zocor, Fosamax Take Hit From Generic Rivals
February 7, 2006
Merck’s profits were up 2 percent in the fourth quarter but overseas generic competition hurt sales of its two key drugs: cholesterol drug Zocor and osteoporosis drug Fosamax.